Removal of Protein-Bound, Hydrophobic Uremic Toxins by a Combined Fractionated Plasma Separation and Adsorption Technique

• Published in: Artificial organs Vol. 37; no. 4; pp. 409 - 416
• Main Authors: Brettschneider, Falko, Tölle, Markus, von der Giet, Markus, Passlick-Deetjen, Jutta, Steppan, Sonja, Peter, Mirjam, Jankowski, Vera, Krause, Alfred, Kühne, Sophie, Zidek, Walter, Jankowski, Joachim
• Format: Journal Article
• Language: English
• Published: United States Blackwell Publishing Ltd 01.04.2013; Wiley Subscription Services, Inc
• Subjects: Adsorber; Adsorption; Blood Proteins - metabolism; Chronic kidney disease; Cresols - blood; Cresols - isolation & purification; Cresols - metabolism; Hemodialysis; Humans; Indican - blood; Indican - isolation & purification; Indican - metabolism; Medical treatment; Phenylacetates - blood; Phenylacetates - isolation & purification; Phenylacetates - metabolism; Pilot Projects; Plasma; Plasmapheresis - methods; Protein Binding; Protein bound; Proteins; Renal Dialysis - methods; Sulfuric Acid Esters - blood; Sulfuric Acid Esters - isolation & purification; Sulfuric Acid Esters - metabolism; Toxins; Uremia - blood; Uremia - metabolism; Uremia - therapy; Uremic toxins
• ISSN: 0160-564X; 1525-1594
• DOI: 10.1111/j.1525-1594.2012.01570.x

Protein‐bound uremic toxins, such as phenylacetic acid, indoxyl sulfate, and p‐cresyl sulfate, contribute substantially to the progression of chronic kidney disease (CKD) and cardiovascular disease (CVD). However, based on their protein binding, these hydrophobic uremic toxins are poorly cleared during conventional dialysis and thus accumulate in CKD‐5D patients. Therefore, we investigated whether hydrophobic and cationic adsorbers are more effective for removal of protein‐bound, hydrophobic uremic toxins than conventional high‐flux hemodialyzer. Five CKD‐5D patients were treated using the fractionated plasma separation, adsorption, and dialysis (FPAD) system for 5 h. A control group of five CKD patients was treated with conventional high‐flux hemodialysis. Plasma concentrations of phenylacetic acid, indoxyl sulfate, and p‐cresyl sulfate were measured. Removal rates of FPAD treatment in comparison to conventional high‐flux hemodialysis were increased by 130% for phenylacetic acid, 187% for indoxyl sulfate, and 127% for p‐cresol. FPAD treatment was tolerated well in terms of clinically relevant biochemical parameters. However, patients suffered from mild nausea 2 h after the start of the treatment, which persisted until the end of treatment. Due to the high impact of protein‐bound, hydrophobic uremic toxins on progression of CKD and CVD in CKD‐5D patients, the use of an adsorber in combination with dialysis membranes may be a new therapeutic option to increase the removal rate of these uremic toxins. However, larger, long‐term prospective clinical trials are needed to demonstrate the impact on clinical outcome.